ABL Texcell Diagnostics (formerly ABL Diagnostics) specializes in the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases (AIDS, viral hepatitis and tuberculosis) by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. Export accounts for 69.7% of net sales.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-10-30	€2.280	+0.88%	10,284
26-10-29	€2.260	+0.89%	7,900
26-10-28	€2.240	-6.67%	12,615
26-10-27	€2.400	0.00%	5,894
26-10-26	€2.400	+0.84%	382

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - ABL Texcell Diagnostics

Company calendar

Market Closed - Euronext Paris 12:55:00 2026-10-30 EDT			5-day change	1st Jan Change
2.280 ^EUR	+0.88%		-4.20%	-24.00%

10-21	ABL Texcell Diagnostics Ends Proposed Acquisition of Vela's US, Singapore Operations	MT
10-19	ABL Texcell Diagnostics SA cancelled to acquire Vela Diagnostics Usa, Inc. and Vela Operations Singapore Pte Ltd. from VDH Holding Pte. Ltd.	CI

Market Cap	36.64M 40.91M 33.7M 30.54M 57.08M 3.88B 58.15M 402M 161M 2.04B 154M 150M 6.44B	P/E 2024	123x	P/E 2025	50x
Enterprise Value	37.57M 41.95M 34.56M 31.31M 58.53M 3.98B 59.63M 412M 165M 2.1B 157M 154M 6.61B	EV / Sales 2024	7,098,474x	EV / Sales 2025	6,185,843x
Free-Float	6.2%	Yield 2024	2.03%	Yield 2025	3.67%

Markets		Quality
Euronext Paris	ABLD	Real-time
CBOE	0OPO	Real-time
CBOE	FAUVp	Real-time
Deutsche Boerse AG	9BK0	Delayed
Börse Stuttgart	9BK0	Delayed

10-21	ABL Texcell Diagnostics Ends Proposed Acquisition of Vela's US, Singapore Operations	MT
10-19	ABL Texcell Diagnostics SA cancelled to acquire Vela Diagnostics Usa, Inc. and Vela Operations Singapore Pte Ltd. from VDH Holding Pte. Ltd.	CI
10-12	ABL Texcell Diagnostics to Acquire French Biotech Company IntegraGen	MT
10-11	ABL Diagnostics Société anonyme completed the acquisition of Business operations and assets of IntegraGen SA for ?0.1 million.	CI
10-01	ABL Diagnostics Revises Revenue Guidance for the Financial Year 2026	CI
09-22	ABL Texcell Diagnostics Signs LoI to Acquire Vela's US, Singapore Operations	MT
09-20	ABL Texcell Diagnostics SA signed a letter of intent to acquire Vela Diagnostics Usa, Inc. and Vela Operations Singapore Pte Ltd. from VDH Holding Pte. Ltd.	CI
09-18	ABL Diagnostics Shareholders Approve Name Change; Euronext Paris Listing to Remain	MT
09-17	ABL Diagnostics Société anonyme has Changed its Name to ABL Texcell Diagnostics	CI
09-11	ABL Diagnostics Société anonyme proposed to acquire Business operations and assets of IntegraGen SA.	CI
09-11	ABL Diagnostics Offers to Acquire IntegraGen Amid Reorganization Proceedings	MT
09-11	Abionyx Pharma Partners With ABL Diagnostics Division for Viral Safety Testing of CER-001	MT
09-10	Abionyx Pharma Enters into Strategic Partnership with TEXCELL (Abl Diagnostics) for Viral Safety and Clearance of Biologics	CI

ABL Texcell Diagnostics Stock

Stocks

ABLD

FR001400AHX6

Medical Equipment, Supplies & Distribution

Valuation: ABL Texcell Diagnostics

Chart: ABL Texcell Diagnostics

Latest news: ABL Texcell Diagnostics

Press Releases: ABL Texcell Diagnostics

News in other languages: ABL Texcell Diagnostics

Quotes and Performance

Price Extremes

Managers and Directors: ABL Texcell Diagnostics

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

10-20	ABL Texcell Diagnostics Announces Termination of Vela Diagnostics Letter of Intent	BU
10-19	ABL Texcell Diagnostics Strengthens the Foundations of a Stable Shareholder Base and Pursues Its Growth Strategy	BU
10-16	ABL Texcell Diagnostics: Notice of Appeal by the Public Prosecutor Regarding the IntegraGen Transfer Judgment	BU
10-12	ABL Texcell Diagnostics Strengthens Its Presence at Genopole and Opens a New Chapter in Precision Oncology With the Acquisition of IntegraGen’s Assets and Operations	BU
10-08	ABL Texcell Diagnostics Announces Availability of All Invest Securities Research Flash Note #8	BU

10-21	Bourse : EssilorLuxottica qui rit, Michelin, Eurofins et Carrefour qui pleurent
10-21	SpaceX et Super Micro en pompiers de la tech
10-20	ABL TEXCELL DIAGNOSTICS ANNONCE LA RÉSILIATION DE LA LETTRE D’INTENTION RELATIVE À VELA DIAGNOSTICS
10-19	ABL TEXCELL DIAGNOSTICS RENFORCE LES CONDITIONS D’UN ACTIONNARIAT STABLE ET POURSUIT SA STRATÉGIE DE CROISSANCE
10-16	ABL TEXCELL DIAGNOSTICS : DÉCLARATION D’APPEL DU MINISTÈRE PUBLIC RELATIVE AU JUGEMENT DE CESSION D’INTEGRAGEN

1 day	+0.88%
1 week	-4.20%
Current month	+1.79%
1 month	+1.79%
3 months	-7.32%
6 months	-3.39%
Current year	-24.00%

1 week	2.18	2.52
1 month	2.1	2.6
Current year	2.1	5
1 year	2.1	5
3 years	2.1	9.7
5 years	1.99	26
10 years	1.28	26

Director	Title	Age	Since
Noemie Sadoun CHM	Chairman	-	-
Laure Raffaelli BRD	Director/Board Member	-	-
Deborah Szafir BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/28/26	Advanced Biological Laboratories SA	Sell	Company	-60,000	0.3723%
7/20/26	Advanced Biological Laboratories SA	Sell	Company	-65,616	0.4072%
7/6/26	Advanced Biological Laboratories SA	Sell	Company	-62,308	0.3867%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABL TEXCELL DIAGNOSTICS	+0.88%	-4.20%	-49.33%	-76.49%	40.55M
ABBOTT LABORATORIES	+1.56%	+3.60%	-14.65%	+14.38%	181B
STRYKER CORPORATION	-6.38%	-4.96%	-21.03%	+11.44%	120B
MEDTRONIC PLC	-0.59%	-0.05%	+5.24%	+39.05%	119B
ESSILORLUXOTTICA	+3.42%	+4.04%	-42.10%	+9.69%	91.44B
CENCORA, INC.	+0.09%	-2.26%	-0.70%	+76.32%	63.07B
HOYA CORPORATION	-0.46%	-0.64%	+9.87%	+80.82%	55.8B
BECTON, DICKINSON AND COMPANY	-0.23%	-1.27%	+9.01%	-21.35%	54.03B
IDEXX LABORATORIES, INC.	-4.30%	-2.74%	-12.18%	+40.84%	45.38B
ALCON INC.	+0.58%	+2.18%	-0.54%	-6.40%	34.37B
Average	-0.62%	-0.07%	-11.64%	+16.83%	76.35B
Weighted average by Cap.	-0.69%	+0.76%	-10.44%	+25.27%

	2024	2025
Net sales	5.87 6.55 5.4 4.89 9.14 622.27 9.32 64.38 25.85 327.33 24.6 24.07 1.03K	7.97 8.89 7.33 6.64 12.41 844.51 12.64 87.38 35.08 444.24 33.38 32.67 1.4K
Net income	285K 318K 262K 238K 444K 30.23M 453K 3.13M 1.26M 15.9M 1.19M 1.17M 50.15M	987K 1.1M 908K 822K 1.54M 105M 1.57M 10.82M 4.34M 55.03M 4.13M 4.05M 174M
Net Debt	2.02M 2.26M 1.86M 1.69M 3.15M 215M 3.21M 22.2M 8.91M 113M 8.48M 8.3M 356M	933K 1.04M 858K 777K 1.45M 98.88M 1.48M 10.23M 4.11M 52.01M 3.91M 3.83M 164M